35 stories
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.
The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.
Analysts expect Novo's aggressive cuts to capture the lion's share of India's GLP-1 market in 12-18 months. Eli Lilly's Mounjaro currently dominates with ~79% share vs Novo's ~21%.
Lilly and startup Baseline Therapeutics are investigating GLP-1 RAs for alcohol and substance use disorders. A large VA study found GLP-1s associated with reduced substance abuse risk, in a therapeutic area projected to reach $12.4B by 2033.
CancerNetwork reviews the latest evidence on thyroid cancer risk associated with GLP-1 RAs like Ozempic and Mounjaro, providing clinicians with an updated risk-benefit assessment for long-term prescribing.
APC CEO Scott Brunner discusses the regulatory landscape for compounded GLP-1 receptor agonists amid increasing scrutiny and legal battles over compounded peptide drugs.
A BMJ-published study of over 600,000 US veterans found GLP-1 medications tied to reduced risk of substance use disorders across all major addictive substances, plus reduced overdose and death risk.
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Viking enrolled ~1,000 adults in the 78-week trial of VK2735, a GLP-1/GIP dual agonist. Phase 2 showed up to 14.7% body weight reduction in just 13 weeks.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
The MHRA told Parliament that 81,000 doses have been seized in three years, with illegal GLP-1 profit margins rivaling class A drugs.
About 1 in 8 US adults now report taking a GLP-1 drug per KFF. Experts caution effects are larger and longer-lasting when combined with lifestyle changes.
New data shows GLP-1 adherence drops significantly after the first year, with cost as a major factor. Insurance gaps and lack of mandated weight loss coverage pose barriers.